Navigation Links
KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Date:2/15/2008

Fiscal 2007 Marked Record Profitability and 12th Consecutive Year of Record

Revenues KV Also Reports Preliminary Fiscal 2008 Third Quarter Revenues of $164

Million, Up 39% from Prior Year

ST. LOUIS, Feb. 15 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded and generic/non-branded prescription pharmaceutical products, reported today its consolidated results of operations for the 2007 fiscal year ended March 31, 2007. The results have been delayed primarily due to the previously reported investigation by a Special Committee of independent members of the Board of Directors into the Company's former stock option grant practices.

KV is nearing completion of work to restate financial results for the periods affected. In addition to the fiscal 2007 results, KV has also included the following items with today's release:
-- restated consolidated results for fiscal years 2005 and 2006;

-- balance sheets as of March 31, 2007 and March 31, 2006 (as restated);

-- a reconciliation of the income statements as restated for fiscal years

2005 and 2006 and the income statements as originally reported; and

-- a reconciliation of the year-end 2006 balance sheet as restated

compared to the year-end 2006 balance sheet as originally reported.

The Company also announced that NYSE Regulation, Inc. today granted the Company's request for a trading extension through March 31, 2008, subject to ongoing reassessment. The extension was required under the Exchange's rules due to the Company's delayed filing of its fiscal 2007 Annual Report on Form 10-K with the Securities and Exchange Commission. The Company expects to have resolved all outstanding issues needed to make this filing and to complete its fiscal 2007 f
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
3. NUCRYST Pharmaceuticals announces year-end results
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
8. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
9. Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation
10. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
11. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... of Western Ontario has received over $603,000 from the Canadian ... a group of bacterial toxins leads to the development of ... is an associate professor in the Department of Microbiology and ... a scientist with the Lawson Health Research Institute. His ...
... (UV) radiation from sunlight may be associated with the ... to a study by researchers at the National Institute ... Institutes of Health. "This study found that women ... exposure when they developed an autoimmune muscle disease called ...
... July 30, 2009 Scientists at Washington University School ... in the liver that helps process fat and glucose. ... additive lecithin, and researchers speculate it may one day ... lipids and reduce risk for diabetes, hypertension or cardiovascular ...
... , , , ... $230,000 for Augie,s Quest, the fast-track research arm of the Muscular Dystrophy ... is dedicated to beating the previous goal by reaching $300,000 in donations ... Bally club now through August 31 and receive a free guest pass ...
... more apt to have joint replacement, study finds , THURSDAY, ... strongly predict the risk of hip and knee joint replacement ... , The research involved 912 healthy people in Italy, including ... or hip replacement between 1990 and 2005. Those with high ...
... , , , ... Mark Rodgers today announced that The Guardian House Alzheimer Care Facility ... commercial location to install the SamarionSolution, The Guardian House is a ... in caring for residents diagnosed with Alzheimer,s or dementia. The ...
Cached Medicine News:Health News:Sun exposure may trigger certain autoimmune diseases in women 2Health News:Food additive may one day help control blood lipids and reduce disease risk 2Health News:Food additive may one day help control blood lipids and reduce disease risk 3Health News:Bally Total Fitness Flexes Fundraising Muscle to Fight ALS 2Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:The First SamarionSolution Installed in Lake Charles Alzheimer's Facility 2
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
Inquire...
Medicine Products: